Perimeter Medical Imaging Ai Inc Stock Price, News & Analysis

Perimeter Medical Imaging AI (OTCQX:PYNKF) has appointed renowned surgical oncologist Dr. Ted James as Chief Medical Officer in a fractional role. Dr. James joins from his position as System Physician Executive of the Endeavor Health Cancer Institute and brings extensive experience from his previous role as Chief of Breast Surgical Oncology at Beth Israel Deaconess Medical Center.

Dr. James, who holds a Master of Science in Healthcare Management from Harvard and served as an Associate Professor of Surgery at Harvard Medical School, will help strengthen Perimeter's medical strategy and accelerate the adoption of its AI-enabled technology for margin assessment in breast cancer surgery. His appointment comes at a crucial time as the company works toward FDA approval of its next-generation AI-enabled Perimeter B-Series.

[ "Appointment of highly qualified CMO with extensive surgical oncology and leadership experience", "Strategic addition to advance FDA approval process for B-Series technology", "New CMO brings Harvard Medical School and Beth Israel Deaconess Medical Center credentials" ]

Perimeter Medical Imaging AI (OTCQX:PYNKF) reported strong Q2 2025 financial results, with revenue reaching $506,000, a 105% increase year-over-year. The company's Perimeter S-Series OCT device showed significant market traction, with case volumes up 93% YoY and 35% QoQ, having imaged over 3,000 patients to date.

The company's next-generation Perimeter B-Series device, combining AI with OCT technology, achieved positive pivotal trial results with a statistically significant reduction in residual cancer during surgery (p=0.0050). The company completed a two-tranche financing, raising total gross proceeds of approximately $3.8 million.

Q2 2025 financial highlights include a 70% gross margin and reduced operating expenses of $4.3 million, down 22% YoY. Net loss was $3.9 million ($0.04 per share), with cash position at $1.4 million as of June 30, 2025.

Perimeter Medical Imaging AI (OTCQX:PYNKF) reported strong preliminary Q2 2025 results, with expected revenue of $500,000, representing a 100% year-over-year growth. The company projects H1 2025 revenue of $1.0 million, already surpassing full-year 2024 revenue of $846,000.

The company announced a significant 30% reduction in operating costs starting Q3 2025, alongside key leadership appointments including Abbey Goodman as VP of Sales and Paolo DiPasquale as VP of Corporate Development. Additionally, Perimeter established an Industry Advisory Board (IAB) to be chaired by Diana Chan, while COO Tom Boon retired but will continue serving on the IAB.

Q2 2025 highlights include 35% procedure growth, 50% sequential recurring revenue growth, and an expected gross margin of 69%.

Perimeter Medical Imaging AI (OTCQX:PYNKF) announced that Medical City Dallas Hospital, an 899-bed acute care facility, has adopted their S-Series OCT imaging technology for surgical procedures. This adoption follows the hospital's participation in a pivotal trial of Perimeter's next-generation B-Series device, which combines OCT with AI technology for breast-conserving surgeries.

The S-Series OCT technology, FDA-cleared in 2021, provides high-resolution visualization of tissue microstructures at the cellular level, offering superior imaging capabilities compared to traditional methods like X-ray, MRI, or ultrasound. The system is optimized to identify regions of interest in tissue microstructures down to 2mm, making it particularly effective for visualizing surgical margins.

Perimeter Medical Imaging AI (PYNKF) announced that CEO Adrian Mendes will deliver a business update presentation at the Life Sciences Virtual Investor Forum on June 12, 2025, at 12:30 p.m. Eastern Time. The commercial-stage medical technology company will make the presentation available via live stream, which will be accessible through their website's Investors section and archived for approximately 90 days.

Perimeter Medical Imaging AI has launched the OCT-Tissue Surveillance Registry, a database aimed at collecting thousands of surgical procedure images and data using their imaging technology. The registry will support future product development and enhance their AI deep-learning model. The company's S-Series OCT technology provides real-time, ultra-high resolution visualization of tissue specimens during surgery. Their next-generation B-Series OCT with ImgAssist AI 2.0, currently under FDA review, integrates AI to help detect suspicious tissue during breast-conserving surgery. Dr. Jennifer Tittensor, who has used the technology in over 120 surgeries, highlighted its value in assessing margins in real-time. The registry will help gather diverse patient data to improve AI algorithm training, potentially leading to more personalized care and reduced need for second surgeries.

Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) has partnered with Intermountain Health, the largest nonprofit health system in the Intermountain West, through a Development Support Agreement (DSA). The collaboration aims to study the value of Perimeter's Optical Coherence Tomography (OCT) technology and gather data for AI algorithm development.

The initial study will analyze reoperation rates and healthcare costs for breast-conserving surgery (BCS) patients at select hospitals. The partnership will support Perimeter's FDA PMA approval process for their AI-enabled OCT system and potential expansion into other tissue types beyond breast surgery.

Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and webcast at 5:00 pm Eastern Time to discuss the results and provide a corporate update. Investors can access the call via 1-800-717-1738 (Canada/US) or 1-646-307-1865 (International). The webcast will be available live and archived on Perimeter's website in the Investors section under "News/Events".

Perimeter Medical Imaging AI presented detailed results from their pivotal trial of B-Series OCT with ImgAssist AI 2.0 for breast cancer surgery margin assessment at ASBrS 2025. The trial met its primary endpoint with statistically significant results (p=0.0050), demonstrating super-superiority compared to standard care. Key findings include: - Among 206 patients, the system correctly detected residual disease in 40% of cases (14/35 patients) after standard care - Completely cleared residual disease in 20% of additional patients - Achieved 88.1% overall margin accuracy - Required minimal additional tissue removal (only 3.8% of total volume) - Benefited 26 patients clinically, including 6 cases where the system detected disease missed by both standard care and histopathology The company has submitted a Premarket Approval application to the FDA in March 2025 for use during breast-conserving surgeries.